# Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.

> **NCT03028909** · PHASE2 · WITHDRAWN · sponsor: **MedImmune LLC**

## Conditions studied

- Influenza - Type A Strains

## Interventions

- **DRUG:** Oseltamivir
- **DRUG:** MEDI8852
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03028909
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-24
- **Primary completion:** 2019-07-26
- **Final completion:** 2019-07-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is withdrawn due to company decision.
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03028909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03028909, "Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03028909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*